Distributing since 1889 • Employee Owned for Better Service
Your 1st Choice!
Sign In
Quick Search:
Cart
|
My Account
|
Print
Ordering
Advanced Search
Fast Order Entry
Express Order Entry
Can't Find Title?
Shopping Cart
Lists
New Receipts
Recall Information
Forthcoming Titles
Latest Price Changes
Downloads
About Us
Home Page
About Matthews
Return Policy
New Account Application
Publisher List
McCoy Medical
Med-Book
Contact Us
Job Opportunities
FAQ
Terms of Use
Product Detail
NOTICE: This is the ProQuest Ebook Central� format of this title.
What is ProQuest Ebook Central�?
Other formats:
Hardcover
All Formats
Cancer Drug Safety and Public Health Policy: A Changing Landscape
Bennett, Charles
Pricing & Availability
Available: Yes*
This title does not qualify for any discount.
Email this title to a friend
Printer friendly version
Other formats:
Hardcover
All Formats
Book Information
Edition:
1st
Publisher:
Springer Nature
ISBN:
3-031-04402-9 (3031044029)
ISBN-13:
978-3-031-04402-1 (9783031044021)
Binding:
E E Book + ProQuest Ebook Central
Copyright:
2022
Publish Date:
12/22
Weight:
0.00 Lbs.
Subject Class:
ONC (Oncology)
Return Policy:
Non-Returnable.
ProQuest Ebook Central�:
Please sign in to preview this title
Class Specifications
Abstract:
This book offers a wide-ranging description and analysis of recent developments and current trends in health policy with regard to cancer drug safety. The book opens with an overview of pharmacovigilance for cancer blockbuster drugs, covering both general considerations and efforts to develop a structured framework for the identification and reporting of adverse drug reactions (ADRs). A number of important examples of serious ADRs to hematology and oncology drugs are then reviewed, with evaluation of the lessons learned and the policy implications of the ensuing legal cases and their settlements. Further, the difficulty of reporting such blockbuster side effects in the medical literature is explored in an empirical study. Significant advances have been achieved in analytic methods for the identification of ADRs, and here there is a particular focus on the value of optimal discriminant analysis. Finally, the impacts on pharmacovigilance and drug safety of the huge fines paid under the U.S. False Claims Act relating to the defrauding of governmental programs also receive careful attention these fines are playing an important role in changing the landscape for pharmaceutical safety.
* Subject to ProQuest Ebook Central� availability
Follow Matthews Book Co. on:
Copyright © 2001-2024 Matthews Book Company - All rights reserved. - 11559 Rock Island Ct., Maryland Heights, MO, 63043 - (800) MED-BOOK
Matthews
Privacy Statement